Get the Stockscreener App
12.28
1.84%
-0.19
Cervomed Inc stock is traded at $12.28, with a volume of 27,592.
It is down -1.84% in the last 24 hours and down -14.70% over the past month.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$12.47
Open:
$12.41
24h Volume:
27,592
Relative Volume:
0.31
Market Cap:
$103.37M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.2872
EPS:
-9.54
Net Cash Flow:
$-7.45M
1W Performance:
-9.20%
1M Performance:
-14.70%
6M Performance:
-49.13%
1Y Performance:
+11.99%
1-Day Range:
$12.20
$12.71
1-Week Range:
$12.20
$14.62
52-Week Range:
$5.85
$26.38
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
Cervomed Inc Stock (CRVO) Latest News
CervoMed Announces Key Takeaways from Oral Presentations at - GlobeNewswire
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - StockTitan
CervoMed Inc. (NASDAQ:CRVO) Short Interest Up 7.6% in October - MarketBeat
CervoMed (NASDAQ:CRVO) Shares Down 3.1% – Time to Sell? - Defense World
CervoMed (NASDAQ:CRVO) Stock Price Down 3.1%What's Next? - MarketBeat
CervoMed to Present Phase 2b Trial Results - TipRanks
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference - GlobeNewswire
Insiders of CervoMed Inc. (NASDAQ:CRVO) were rewarded after last week’s 11% gain - Simply Wall St
CRVOCervoMed Inc. Latest Stock News & Market Updates - StockTitan
CervoMed Announces Last Patient Last Visit in Phase 2b - GlobeNewswire
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) - StockTitan
CervoMed Ends $20 Million Stock Sales Agreement with BTIG - Yahoo Finance
CervoMed ends sales agreement with BTIG By Investing.com - Investing.com South Africa
CervoMed ends sales agreement with BTIG - Investing.com India
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
CervoMed Inc. (NASDAQ:CRVO) Short Interest Update - MarketBeat
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - The Manila Times
CervoMed to present on neflamapimod as DLB treatment at CTAD - TipRanks
CervoMed to Deliver Late-Breaking Oral Presentations at the - GlobeNewswire
Armistice Capital LLC Sells 94,363 Shares of CervoMed Inc. (NASDAQ:CRVO) - MarketBeat
There is no way Cerence Inc (CRNC) can keep these numbers up - SETE News
Credo Technology Group (NASDAQ:CRDO) Trading Up 3% - MarketBeat
Certara Inc (CERT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Closing Figures Unveiled: Cemtrex Inc. (CETX) Drop -3.49, Closes at 0.14 - The Dwinnex
Examining Certara Inc (CERT) more closely is necessary - US Post News
Cerence Inc. (CRNC)’s $40 Million Revenue Guidance Signals Trouble for Investors - Insider Monkey
(CRVO) Technical Pivots with Risk Controls - Stock Traders Daily
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 - StockTitan
Holdings of CERo Therapeutics Holdings Inc. (CERO) are aligned with the stars - SETE News
CERo Therapeutics Holdings Inc. (CERO)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
With 65% ownership, Cerus Corporation (NASDAQ:CERS) boasts of strong institutional backing - Yahoo Finance
Renaissance Technologies LLC Has $8.34 Million Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World
Croda International (OTCMKTS:COIHD) Sets New 52-Week Low at $26.75 - Defense World
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid - Business Wire
A significant driver of top-line growth: Certara Inc (CERT) - SETE News
Cerence Inc’s latest rating changes from various analysts - Knox Daily
Closing Figures Unveiled: Corvus Pharmaceuticals Inc (CRVS) Drop -7.95, Closes at 5.44 - The Dwinnex
Perhaps timely catching Cerus Corp. (CERS) would be a good idea - SETE News
Is it possible to buy Cerence Inc(CRNC) shares at a good price now? - US Post News
Hood River Capital Management LLC Acquires 1,170,060 Shares of Cerus Co. (NASDAQ:CERS) - Defense World
What Makes Criteo (CRTO) an Attractive Pick? - Yahoo Finance
Credo Technology Group Holding Ltd (CRDO) requires closer examination - US Post News
Investing in Cerus Corp. (CERS) Is Getting More Attractive - Knox Daily
‘An Amazing Physical Force’: Richard Spooner Remembers Cristallo - The Chronicle of the Horse
The Potential Rise in the Price of Credo Technology Group Holding Ltd (CRDO) following insiders activity - Knox Daily
Cercle raises USD 6M in seed funding - Medical Buyer
Corvus Pharmaceuticals Inc [CRVS] Stock bought by Insider Jones William Benton for $34624.0 - Knox Daily
Ceva Inc. (CEVA) looking to reclaim success with recent performance - SETE News
Top investors say Criteo S.A ADR (CRTO) ticks everything they need - SETE News
Stock Performance Spotlight: Cerus Corp. (CERS) Ends the Day at 1.80, Down by -1.64 - The Dwinnex
Examining CERo Therapeutics Holdings Inc. (CERO) stock is warranted - US Post News
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):